Advance your research
Join us in Washington
for AACR 2017
April 1 - 5 | Booth #2925

Register now for our exclusive Satellite Symposium

Visualize your Biomarker Expression with RNAscope® Technology

April 4th, 6:45 - 8:15 PM
Independence BCDE & Corridor A

Grand Hyatt Washington

Investigating cancer evolution and heterogeneity using a novel in situ hybridization technology

Ann Marie Baker from the Evolution and Cancer lab at Barts Cancer Institute will present how the utilized RNAscope® technology to study the distribution of LGR5 'stem cells' and c-MYC positive cells in colorectal adenomas and carcinomas and how they applied BaseScope™ to the detection of common point mutations in in archival tumors.

Read the full abstract

Visit us at booth #2925 and see how we visualize data with RNAscope® Technology

What is missing from
your biomarker analysis?

Visualize tumor microenvironments (TMEs) with RNAscope® in situ hybridization technology; delivering unrivaled single-molecule sensitivity and specificity - even for targets like splice variants, highly homologous sequences, and short sequences including CAR-T cell or CRD/TCR clones. The assay has the capacity to reveal molecular and cellular interactions of tumor cells and the immune system. Visualization and quantification of gene expression within the morphological context across the tumor allows insights in the tumor heterogeneity.
  • Detect mRNAs and lncRNAs at single molecule sensitivity using the RNAscope® assay
  • Use Basescope™ to target specific splice junctions for aberrant alternative splicing in cancers
  • Identify point mutations or gene editing with the BaseScop™ assay
  • Characterize expression profiles of various checkpoint markers and therapeutic targets in the TME
  • Perform single cell analysis and glean morphological information in FFPE or frozen tissues
  • Carry out quantitative analysis of co-expression of multiple checkpoint molecules within the same cell

"Meet the scientists" sessions

Meet our ACD's scientists at Booth #2925 and take advantage of an initial scientific consultation on any technical question.

Talk to us:
  • Tell us about your scientific challenges and find out how RNAscope® may help you solve it?
  • Are there RNAscope® probes available for your target(s) of interest?
  • Which assay format (chromogenic/ fluorescent) is optimal for your project and tissue or cell sample (FFPE, fresh or fixed frozen, adherent or suspension cells)?
  • What are the optimal experimental controls?
  • Determine the optimal design for your experiments (e.g. combine RNAscope® assay with IHC or IF)?

Schedule (to be confirmed):
  • Sunday September 17, 11:00 to 1:00
  • Monday September 18, 11:00 to 1:00

FIGURE 1: Four-plex detection of biomarker and checkpoint markers in FFPE Lung Cancer tissues stained with RNAscope® Multiplex Fluorescent Assay v2 and RNAscope® 4-Plex Ancillary Kit: KRT19 (green), CD8A (yellow), CD4 (red), CD68 (white).

FIGURE 2: Simultaneous detection of CD8A (red) and PD-L1 (green) in NSCLC tissue using RNAscope® 2.5 HD Duplex Assay

Check out all RNAscope® technology related posters

Enter now - You could win a brand new BMW 330e hybrid.